Physician profile
Kami Bell
NPI 1417355694
$7,345.17
in general payments reported to CMS, 2019-2025
22 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $1,759 · 2023: $1,416 · 2024: $1,569 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472 · Education: $40.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.26 |
| Education | $40.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,803.35 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $1,361.68 | 2021-2025 | Biktarvy, Veklury |
| Astellas Pharma US INC | $827.40 | 2021-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $739.17 | 2021-2025 | Zerbaxa, Dificid, Delstrigo |
| Melinta Therapeutics, LLC | $724.64 | 2021-2025 | Kimyrsa, Rezzayo, Vabomere |
| Paratek Pharmaceuticals, INC. | $528.13 | 2021-2024 | Nuzyra |
| Abbvie INC. | $486.76 | 2021-2025 | |
| Shionogi INC | $229.22 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $97.43 | 2021-2023 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $79.79 | 2021-2023 | Symtuza |
| Insmed, INC. | $75.36 | 2023-2025 | Arikayce |
| La Jolla Pharmaceutical Company | $63.45 | 2022-2025 | Xerava, Zevtera |
| Cumberland Pharmaceuticals, INC. | $56.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.00 | 2021-2023 | Relistor |
| Intercept Pharmaceuticals, INC. | $48.60 | 2021-2023 | Ocaliva |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.64 | 2022-2023 | Gattex |
| Pharmacosmos Therapeutics INC. | $36.08 | 2022 | |
| Ethicon US, LLC | $21.45 | 2022 | |
| Invivyd INC | $19.27 | 2024 | Pemgarda |
| Aimmune Therapeutics, INC. | $18.76 | 2025 | Vowst |
| Organogenesis INC. | $17.43 | 2025 | Puraply Wound Matrix |
| Pfizer INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.